<DOC>
	<DOCNO>NCT02232659</DOCNO>
	<brief_summary>The SynCardia 70cc temporary Total Artificial Heart ( TAH-t ) approve U.S. Food Drug Administration ( FDA ) use bridge transplant patient risk imminent ( happen ) death irreversible biventricular heart failure . The purpose research study evaluate whether TAH-t support patient life-threatening irreversible biventricular heart failure eligible transplantation . The TAH-t , use patient eligible transplant , consider investigational ( approved FDA ) use . This use call destination therapy ( DT ) . Nineteen ( 19 ) patient life-threatening , biventricular failure eligible cardiac transplant enrol Primary Arm study follow six month post-TAH-t implant . Safety evaluate review adverse event experience enrolled subject compare previous experience TAH-t patient wait heart transplant . Since approximately 74 % patient condition would expect live beyond six month , benefit TAH-t DT confirm base survival six month without experience permanent disable stroke-related deficit . After six month follow-up visit , patient continue follow study five ( 5 ) year postTAH-t implant [ every six month two year support TAH-t implant annually another three year ] . Up additional 19 patient may enrol Secondary Arm study characterize use TAH-t DT broader patient population . Follow-up would patient enrol arm study .</brief_summary>
	<brief_title>SynCardia 70cc TAH-t Destination Therapy ( DT )</brief_title>
	<detailed_description>On 15 October 2004 , SynCardia temporary Total Artificial Heart ( TAH-t ) receive Food Drug Administration ( FDA ) approval ( Premarket Approval Application [ PMA ] # P030011 ) in-hospital use bridge transplant ( BTT ) cardiac transplant-eligible candidate risk imminent death biventricular failure . On 2 March 2012 , FDA grant Humanitarian Use Designation ( HUD ) 70cc TAH-t System use Destination Therapy ( DT ) patient risk imminent death irreversible biventricular heart failure eligible transplant body surface area ( BSA ) &gt; 1.7m . This clinical study intend determine safety probable benefit 70cc TAH-t use DT support Humanitarian Device Exemption ( HDE ) application new indication TAH-t System . The SynCardia TAH-t System pulsatile biventricular device replaces patient 's native ventricle valve pump blood pulmonary systemic circulation . The TAH-t System DT consist implantable TAH-t SynHall Valves , power PMA-approved external pneumatic driver [ Circulatory Support System ( CSS ) Console , Companion 2 Driver System Freedom Driver System ] . The TAH-t System intend implanted operating room qualify surgeon capable support patient inside outside hospital . The SynCardia TAH-t DT indicate refractory advanced heart failure patient biventricular failure candidate cardiac transplant presence contraindication transplant , include cancer , advanced age , obesity , end-stage diabetes mellitus , high panel reactive antibody ( PRAs ) , non-cardiac congenital defect , contraindication immunosuppression , lack social support , poor medical compliance , neurological impairment co-morbidities poor prognosis survival . Patients life-threatening , irreversible biventricular failure eligible transplant currently alternative death . The rationale conduct study base result clinical study bridge-to-transplant ( BTT ) patient population , together vitro design verification validation testing , vitro reliability testing , clinical reliability experience thirty year . The study design prospective , non-randomized , two-treatment arm , multi-center study . Nineteen ( 19 ) patient enrol Primary Arm 30 investigational site support HDE use TAH-t DT . Up additional 19 patient may enrol Secondary Arm futher characterize use TAH-t DT broader patient population . Patients treat 70cc TAH-t System DT Primary Arm adult male female patient age 19 75 year old BSA ≥1.7m2 life-threatening irreversible biventricular failure eligible heart transplant ( determined implant center time implant assessment ) meet enrollment criterion define clinical protocol . Patients treat 70cc TAH-t System DT Secondary Arm adult male female patient least 19 year old , eligible heart transplant ( determined implant center time implant assessment ) , meet less restrictive enrollment criterion define clinical protocol . The risk TAH-t subject expose clinical investigation expect well-characterized risk PMA-approved TAH-t System use bridge-to-transplant population mitigate design test TAH-t System . The primary objective SynCardia temporary Total Artificial Heart ( TAH-t ) DT Study evaluate whether TAH-t support patient life-threatening irreversible biventricular heart failure ineligible cardiac transplantation ( determined implant center time implant screen assessment ) , without experience permanent disable stroke-related deficit ( evidence Modified Rankin Scale score 0 - 2 ) . The primary objective study evaluate whether safety profile device , use DT , acceptable . Probable benefit define survival six month TAH-t System support implant TAH-t , without experience permanent disable stroke-related deficit . This patient population , without treatment , poor prognosis survival . Per M.L.A . Haeck , `` Patients drug refractory end-stage HF [ heart failure ] receive support inotropic drug [ ] 3- , 6- , 12-month survival 51 % , 26 % , 6 % , respectively , mean survival 3.4 month . `` 1 The study success criterion : alive original TAH-t free permanent disable stroke-related deficit ( evidence Modified Rankin Scale score 0 - 2 ) six month post-implant ( transplanted prior six month post-implant ) . For study consider success , eight 19 subject either must alive six month original TAH-t implant , without experience permanent disable stroke deficit , become transplant eligible ( transplant ) . The safety endpoint capture accord Intermacs Registry AE definition assess accord data collection schedule follow Intermacs Registry protocol . Secondary safety endpoint incidence major infection ( sepsis ) , neurological event ( ischemic hemorrhagic cardiovascular accident [ CVA ] ) , chronic renal dysfunction , rate major device failures/malfunctions , define per Intermacs definition . A performance goal establish base previous experience TAH-t patient wait heart transplant . All subject follow study date TAH-t implant six month post-implant , cardiac transplantation , death , withdrawal study , whichever occur first . Data six month post-TAH-t implant period use support HDE application . After six month follow-up visit , patient continue follow study five ( 5 ) year post-TAH-t implant [ every six month two year support TAH-t implant annually another three year ] . 1 Neth Heart J ( 2012 ) 20:167-175 15 November 2011</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Primary Arm 1 . Patients ifethreatening , irreversible biventricular heart failure ( Intermacs Patient Profile Classifications 1 4 ) 2 . Ineligible cardiac transplantation ( e.g. , contraindication immunosuppression , cancer , elevate panel reactive antibody [ PRAs ] ) determine implant center time implant screening assessment . 3 . On optimal medical management fail respond fail DT VAD therapy ( continue decline ) 4 . Ambulatory without assistance 5 . Patients 19 75 year age 6 . Patients Body Surface Area ( BSA ) ≥ 1.7m2 7 . Sternum T10 distance &gt; 10cm OR adequate room chest determine 3D image assessment standard clinical assessment 1 . Cardiac transplanteligible patient 2 . Patients adequately anticoagulated TAHt 3 . Patients insufficient space chest 4 . Patients ECMO support 5 . Patients Cirrhosis ( evidence ultrasound , CT scan , positive biopsy ) 6 . Patients Acute Chronic Renal dysfunction ( per Intermacs AE Definitions ) 7 . Patients cardiac cachexia ( e.g. , prealbumin &lt; 17 , fragility , catabolic/anabolic imbalance ) 8 . Patients comorbidity poor prognosis survival beyond six month 9 . Patients insufficient social support demonstrate noncompliance medical instruction ( determine Principal Investigator ) Secondary Arm 1 . Patients NOT eligible participate Primary Arm 2 . Patients lifethreatening , irreversible biventricular heart failure ( Intermacs Patient Profile Classifications 1 7 ) 3 . Ineligible cardiac transplantation ( determined implant center time implant screen assessment ) . 4 . On optimal medical management fail respond fail DT VAD therapy ( continue decline ) 5 . Patients 19 year age old 6 . Sternum T10 distance &gt; 10cm OR adequate room chest determine 3D image assessment standard clinical assessment 1 . Patients le 19 year old 2 . Cardiac transplanteligible patient 3 . Patients Cirrhosis ( evidence ultrasound , CT scan , positive biopsy ) 4 . Patients Chronic Renal dysfunction ( per Intermacs AE Definitions ) 5 . Patients insufficient space chest 6 . Patients adequately anticoagulated TAHt 7 . Patients insufficient social support demonstrate noncompliance medical instruction ( determine Principal Investigator )</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>SynCardia</keyword>
	<keyword>Total Artificial Heart</keyword>
	<keyword>Biventricular heart failure</keyword>
	<keyword>Ineligible cardiac transplant</keyword>
</DOC>